US Patent Issued to Aadigen on Oct. 27 for "Compositions for treating cancer with KRAS mutations and uses thereof" (American, French Inventors)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,774,463, issued on Oct. 27, was assigned to Aadigen LLC (Pacific Palisades, Calif.).

"Compositions for treating cancer with KRAS mutations and uses thereof" was invented by Neil P. Desai (Pacific Palisades, Calif.) and Gilles Divita (St. Andre de Sangonis, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present application provides guide RNAs and genome-editing complexes or nanoparticles that are useful for specifically targeting a mutated KRAS. Exemplary genome-editing complexes or nanoparticles comprise cell-penetrating peptides, and optionally a DNA nuclease (such as Cas9) or a polynucleotide encoding the DNA nuclease."

The patent was file...